OrbusNeich granted approval to market Genous stent in Taiwan

The Genous stent is coated with an antibody to capture a patient’s endothelial progenitor cells (EPC) circulating in the bloodstream. When attracted to the inner surface of the Genous stent, EPCs have been shown to quickly form a healthy layer of endothelium that minimizes stent restenosis and provides protection against stent thrombosis.

Teddy Chien, chairman of OrbusNeich, said: “The introduction of our pro-healing stent to the Taiwanese market is an important step for our company as we expand our presence in the Asia-Pacific region. Based on our interaction with Taiwanese physicians, we expect strong Genous sales from the outset because of the demand for safe alternatives to drug-eluting stents.”